Zynerba Pharmaceuticals, Inc. (ZYNE) |
|
0.4302 -0.025 (-5.45%)
|
03-24 16:00 |
|
Open: |
0.41 |
Pre. Close: |
0.455 |
|
High:
|
0.448 |
Low:
|
0.41 |
|
Volume:
|
81,458 |
Market Cap:
|
20(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:31:47 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 0.57 One year: 0.65 |
| Support: |
Support1: 0.38 Support2: 0.32 |
| Resistance: |
Resistance1: 0.49 Resistance2: 0.56 |
| Pivot: |
0.44 |
| Moving Average: |
MA(5): 0.46 MA(20): 0.45
MA(100): 0.56 MA(250): 0.9 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1  |
| Stochastic oscillator: |
%K(14,3): 56.1 %D(3): 68.3 |
| RSI: |
RSI(14): 41.7 |
| 52-week: |
High: 2.15 Low: 0.38 |
| Average Vol(K): |
3-Month: 324 (K) 10-Days: 260 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ZYNE ] has closed above bottom band by 40.3%. Bollinger Bands are 21.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.45 - 0.45 |
0.45 - 0.45 |
|
Low:
|
0.4 - 0.41 |
0.41 - 0.41 |
|
Close:
|
0.43 - 0.43 |
0.43 - 0.43 |
|
Company Description |
|
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. |
Headline News |
Thu, 23 Mar 2023
What is Wall Street's Target Price for Zynerba Pharmaceuticals Inc (ZYNE) Stock Thursday? - InvestorsObserver
Tue, 21 Mar 2023
North American Morning Briefing : Stock Futures -2- - Marketscreener.com
Mon, 13 Mar 2023
Zynerba Pharmaceuticals Confirms Not Holding Cash Deposits or Securities at Silicon Valley Bank - Marketscreener.com
Thu, 09 Mar 2023
Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd ... - MyChesCo
Tue, 07 Mar 2023
Where Will Zynerba Pharmaceuticals Inc (ZYNE) Stock Go Next After It Is Lower By 0.00% in a Week? - InvestorsObserver
Tue, 07 Mar 2023
North American Morning Briefing: Stocks Seen on -2- - Morningstar
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
47 (M) |
| Shares Float |
42 (M) |
|
% Held by Insiders
|
5.2 (%) |
|
% Held by Institutions
|
18.6 (%) |
|
Shares Short
|
182 (K) |
|
Shares Short P.Month
|
76 (K) |
Stock Financials |
|
EPS
|
-1 |
|
EPS Est Next Qtl
|
-0.58 |
|
EPS Est This Year
|
-2.43 |
|
EPS Est Next Year
|
-2.4 |
|
Book Value (p.s.)
|
1.16 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-29.1 |
|
Return on Equity (ttm)
|
-54.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-0.75 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-25 (M) |
|
Levered Free Cash Flow
|
-12 (M) |
Stock Valuations |
|
PE Ratio
|
-0.44 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.36 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.81 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
